These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29854848)

  • 21. Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.
    Hoft DF; Eickhoff CS
    Infect Immun; 2002 Dec; 70(12):6715-25. PubMed ID: 12438346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced cerebral infection of Neospora caninum in BALB/c mice vaccinated with recombinant Brucella abortus RB51 strains expressing N. caninum SRS2 and GRA7 proteins.
    Vemulapalli R; Sanakkayala N; Gulani J; Schurig GG; Boyle SM; Lindsay DS; Sriranganathan N
    Vet Parasitol; 2007 Sep; 148(3-4):219-30. PubMed ID: 17651896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.
    Cerny N; Sánchez Alberti A; Bivona AE; De Marzi MC; Frank FM; Cazorla SI; Malchiodi EL
    Hum Vaccin Immunother; 2016; 12(2):438-50. PubMed ID: 26312947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice.
    Basso B; Cervetta L; Moretti E; Carlier Y; Truyens C
    Vaccine; 2004 May; 22(15-16):1868-72. PubMed ID: 15121297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice.
    de la Cruz JJ; Villanueva-Lizama L; Dzul-Huchim V; Ramírez-Sierra MJ; Martinez-Vega P; Rosado-Vallado M; Ortega-Lopez J; Flores-Pucheta CI; Gillespie P; Zhan B; Bottazzi ME; Hotez PJ; Dumonteil E
    Hum Vaccin Immunother; 2019; 15(1):210-219. PubMed ID: 30192702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs.
    Aparicio-Burgos JE; Ochoa-García L; Zepeda-Escobar JA; Gupta S; Dhiman M; Martínez JS; de Oca-Jiménez RM; Val Arreola M; Barbabosa-Pliego A; Vázquez-Chagoyán JC; Garg NJ
    PLoS Negl Trop Dis; 2011; 5(5):e1050. PubMed ID: 21625470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.
    Jones K; Versteeg L; Damania A; Keegan B; Kendricks A; Pollet J; Cruz-Chan JV; Gusovsky F; Hotez PJ; Bottazzi ME
    Infect Immun; 2018 Apr; 86(4):. PubMed ID: 29311242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant effect of the Propionibacterium acnes and its purified soluble polysaccharide on the immunization with plasmidial DNA containing a Trypanosoma cruzi gene.
    Mussalem JS; Vasconcelos JR; Squaiella CC; Ananias RZ; Braga EG; Rodrigues MM; Longo-Maugéri IM
    Microbiol Immunol; 2006; 50(4):253-63. PubMed ID: 16625047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection.
    Boscardin SB; Kinoshita SS; Fujimura AE; Rodrigues MM
    Infect Immun; 2003 May; 71(5):2744-57. PubMed ID: 12704149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine.
    Rosas-Jorquera CE; Sardinha LR; Pretel FD; Bombeiro AL; D'Império Lima MR; Alvarez JM
    Clin Vaccine Immunol; 2013 Feb; 20(2):248-54. PubMed ID: 23254299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against
    Antonoglou MB; Sánchez Alberti A; Redolfi DM; Bivona AE; Fernández Lynch MJ; Noli Truant S; Sarratea MB; Iannantuono López LV; Malchiodi EL; Fernández MM
    Front Immunol; 2020; 11():1279. PubMed ID: 32695105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A DNA vaccine encoding for TcSSP4 induces protection against acute and chronic infection in experimental Chagas disease.
    Arce-Fonseca M; Ramos-Ligonio A; López-Monteón A; Salgado-Jiménez B; Talamás-Rohana P; Rosales-Encina JL
    Int J Biol Sci; 2011; 7(9):1230-8. PubMed ID: 22110377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.
    Pereira-Chioccola VL; Costa F; Ribeirão M; Soares IS; Arena F; Schenkman S; Rodrigues MM
    Parasite Immunol; 1999 Feb; 21(2):103-10. PubMed ID: 10101720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine responses in Trypanosoma cruzi-infected children in Paraguay.
    Samudio M; Montenegro-James S; Cabral M; Martinez J; Rojas de Arias A; James MA
    Am J Trop Med Hyg; 1998 Jan; 58(1):119-21. PubMed ID: 9452302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi.
    Corral RS; Petray PB
    Vaccine; 2000 Sep; 19(2-3):234-42. PubMed ID: 10930678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain immunodominant CD8(+) T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients.
    Egui A; Thomas MC; Morell M; Marañón C; Carrilero B; Segovia M; Puerta CJ; Pinazo MJ; Rosas F; Gascón J; López MC
    Mol Immunol; 2012 Oct; 52(3-4):289-98. PubMed ID: 22750229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response.
    Miller MJ; Wrightsman RA; Manning JE
    Exp Parasitol; 1996 Nov; 84(2):156-67. PubMed ID: 8932765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective immunity induced by a DNA vaccine expressing eIF4A of Toxoplasma gondii against acute toxoplasmosis in mice.
    Chen J; Huang SY; Li ZY; Yuan ZG; Zhou DH; Petersen E; Zhang NZ; Zhu XQ
    Vaccine; 2013 Mar; 31(13):1734-9. PubMed ID: 23370151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.
    Pereira IR; Vilar-Pereira G; Marques V; da Silva AA; Caetano B; Moreira OC; Machado AV; Bruna-Romero O; Rodrigues MM; Gazzinelli RT; Lannes-Vieira J
    PLoS Pathog; 2015 Jan; 11(1):e1004594. PubMed ID: 25617628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells.
    Limon-Flores AY; Cervera-Cetina R; Tzec-Arjona JL; Ek-Macias L; Sánchez-Burgos G; Ramirez-Sierra MJ; Cruz-Chan JV; VanWynsberghe NR; Dumonteil E
    Vaccine; 2010 Oct; 28(46):7414-9. PubMed ID: 20850536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.